Intrarenal alterations of the angiotensin-converting enzyme type 2/angiotensin 1-7 complex of the renin-angiotensin system do not alter the course of malignant hypertension in Cyp1a1-Ren-2 transgenic rats
- PMID: 26833491
- DOI: 10.1111/1440-1681.12553
Intrarenal alterations of the angiotensin-converting enzyme type 2/angiotensin 1-7 complex of the renin-angiotensin system do not alter the course of malignant hypertension in Cyp1a1-Ren-2 transgenic rats
Abstract
The role of the intrarenal renin-angiotensin system (RAS) in the pathophysiology of malignant hypertension is not fully understood. Accumulating evidence indicates that the recently discovered vasodilator axis of the RAS, angiotensin-converting enzyme (ACE) type 2 (ACE2)/angiotensin 1-7 (ANG 1-7), constitutes an endogenous system counterbalancing the hypertensiogenic axis, ACE/angiotensin II (ANG II)/AT1 receptor. This study aimed to evaluate the role of the intrarenal vasodilator RAS axis in the pathophysiology of ANG II-dependent malignant hypertension in Cyp1a1-Ren-2 transgenic rats. ANG II-dependent malignant hypertension was induced by 13 days' dietary administration of indole-3-carbinol (I3C), a natural xenobiotic that activates the mouse renin gene in Cyp1a1-Ren-2 transgenic rats. It was hypothesized that pharmacologically-induced inhibition of the ACE2/ANG 1-7 complex should aggravate, and activation of this axis should attenuate, the course of ANG II-dependent malignant hypertension. Blood pressure (BP) was monitored by radiotelemetry. ACE2 inhibitor (DX 600, 0.2 μg/day) and ACE2 activator (DIZE, 1 mg/day) were administrated via osmotic minipumps. Even though ACE2 inhibitor significantly decreased and ACE2 activator increased intrarenal ANG 1-7 concentrations, the course of BP, as well as of albuminuria, cardiac hypertrophy and renal glomerular damage, were not altered. It was shown that intrarenal alterations in the ACE2/ANG 1-7 complex did not significantly modify the course of malignant hypertension in I3C-induced Cyp1a1-Ren-2 transgenic rats. Thus, in our experimental setting alterations of this intrarenal vasodilator complex of the RAS do not significantly modify the form of malignant hypertension that clearly depends on the inappropriately increased activity of the ACE/ANG II/AT1 receptor axis.
Keywords: angiotensin 1-7; angiotensin II; angiotensin-converting enzyme type 2; malignant hypertension; renin-angiotensin system.
© 2016 John Wiley & Sons Australia, Ltd.
Similar articles
-
Epoxyeicosatrienoic acid analog attenuates the development of malignant hypertension, but does not reverse it once established: a study in Cyp1a1-Ren-2 transgenic rats.J Hypertens. 2016 Oct;34(10):2008-25. doi: 10.1097/HJH.0000000000001029. J Hypertens. 2016. PMID: 27428043 Free PMC article.
-
Genetic clamping of renin gene expression induces hypertension and elevation of intrarenal Ang II levels of graded severity in Cyp1a1-Ren2 transgenic rats.J Renin Angiotensin Aldosterone Syst. 2006 Jun;7(2):74-86. doi: 10.3317/jraas.2006.013. J Renin Angiotensin Aldosterone Syst. 2006. PMID: 17083061
-
Fenofibrate Attenuates Malignant Hypertension by Suppression of the Renin-angiotensin System: A Study in Cyp1a1-Ren-2 Transgenic Rats.Am J Med Sci. 2016 Dec;352(6):618-630. doi: 10.1016/j.amjms.2016.09.008. Epub 2016 Sep 27. Am J Med Sci. 2016. PMID: 27916218
-
ACE2 and vasoactive peptides: novel players in cardiovascular/renal remodeling and hypertension.Ther Adv Cardiovasc Dis. 2015 Aug;9(4):217-37. doi: 10.1177/1753944715597623. Epub 2015 Aug 13. Ther Adv Cardiovasc Dis. 2015. PMID: 26275770 Review.
-
New insights and perspectives on intrarenal renin-angiotensin system: focus on intracrine/intracellular angiotensin II.Peptides. 2011 Jul;32(7):1551-65. doi: 10.1016/j.peptides.2011.05.012. Epub 2011 Jun 14. Peptides. 2011. PMID: 21699940 Free PMC article. Review.
Cited by
-
Combined Inhibition of Soluble Epoxide Hydrolase and Renin-Angiotensin System Exhibits Superior Renoprotection to Renin-Angiotensin System Blockade in 5/6 Nephrectomized Ren-2 Transgenic Hypertensive Rats with Established Chronic Kidney Disease.Kidney Blood Press Res. 2018;43(2):329-349. doi: 10.1159/000487902. Epub 2018 Mar 6. Kidney Blood Press Res. 2018. PMID: 29529602 Free PMC article.
-
Increased Endogenous Activity of the Renin-Angiotensin System Reduces Infarct Size in the Rats with Early Angiotensin II-dependent Hypertension which Survive the Acute Ischemia/Reperfusion Injury.Front Pharmacol. 2021 May 28;12:679060. doi: 10.3389/fphar.2021.679060. eCollection 2021. Front Pharmacol. 2021. PMID: 34122103 Free PMC article.
-
Angiotensin-converting enzyme 2 and COVID-19: patients, comorbidities, and therapies.Am J Physiol Lung Cell Mol Physiol. 2021 Mar 1;320(3):L301-L330. doi: 10.1152/ajplung.00259.2020. Epub 2020 Nov 25. Am J Physiol Lung Cell Mol Physiol. 2021. PMID: 33237815 Free PMC article. Review.
-
Altered Renal Vascular Responsiveness to Vasoactive Agents in Rats with Angiotensin II-Dependent Hypertension and Congestive Heart Failure.Kidney Blood Press Res. 2019;44(4):792-809. doi: 10.1159/000501688. Epub 2019 Aug 20. Kidney Blood Press Res. 2019. PMID: 31430751 Free PMC article.
-
Epoxyeicosatrienoic acid analog attenuates the development of malignant hypertension, but does not reverse it once established: a study in Cyp1a1-Ren-2 transgenic rats.J Hypertens. 2016 Oct;34(10):2008-25. doi: 10.1097/HJH.0000000000001029. J Hypertens. 2016. PMID: 27428043 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous